Meanwhile, the S&P BSE Sensex was down 83.58 points or 0.24% at 34,362.17. The S&P BSE Mid-Cap index dropped 0.54%, underperforming the Sensex.

On the BSE, 714 shares were traded on the counter so far as against average daily volumes of 2,341 shares in the past one quarter. The stock had hit a high of Rs 806.55 and a low of Rs 771.15 so far during the day. The stock had hit a record high of Rs 1,122 on 8 August 2017 and a 52-week low of Rs 700 on 27 March 2017.

The stock had underperformed the market over the past one month till 26 February 2018, sliding 18.68% compared with the Sensex's 4.45% fall. The stock had also underperformed the market over the past one quarter, declining 21.06% as against the Sensex's 2.28% rise. The scrip had also underperformed the market over the past one year, advancing 3.54% as against the Sensex's 19.22% rise.

The mid-cap company has equity capital of Rs 10.28 crore. Face value per share is Rs 2.

Shares of Vinati Organics had declined 6.21% in the past four trading sessions to settle at Rs 775.85 yesterday, 26 February 2018, from its close of Rs 827.25 on 20 February 2018.

Vinati Organics' net profit fell 9.4% to Rs 31.73 crore on 12.9% growth in net sales to Rs 185.65 crore in Q3 December 2017 over Q3 December 2016.

Vinati Organics manufactures isobutyl benzene, the prime raw material for the manufacture of ibuprofen, a vital bulk drug.

Powered by Capital Market - Live News

The result was announced on Saturday, 3 February 2018.

Meanwhile, the S&P BSE Sensex was down 284.50 points, or 0.81%, to 34,782.25. The S&P BSE Mid-Cap index was down 128.04 points, or 0.72%, to 17,719.49.

On BSE, so far 2,878 shares were traded in the counter as against average daily volume of 2,881 shares in the past one quarter. The stock hit a high of Rs 912.25 and a low of Rs 854 so far during the day. The stock hit a record high of Rs 1,122 on 8 August 2017. The stock hit a 52-week low of Rs 700 on 27 March 2017.

The mid-cap company has equity capital of Rs 10.28 crore. Face value per share is Rs 2.

Vinati Organics manufactures isobutyl benzene, the prime raw material for the manufacture of ibuprofen, a vital bulk drug.

Powered by Capital Market - Live News

Net profit of Vinati Organics declined 9.45% to Rs 31.73 crore in the quarter ended December 2017 as against Rs 35.04 crore during the previous quarter ended December 2016. Sales rose 12.92% to Rs 185.65 crore in the quarter ended December 2017 as against Rs 164.41 crore during the previous quarter ended December 2016.

Powered by Capital Market - Live News

Vinati Organics will hold a meeting of the Board of Directors of the Company on 3 February 2018.

Powered by Capital Market - Live News